test

A Randomized, Multicenter, Double-Blind Phase III Study of PD-0332991 Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women with ER (+), HER2 (-) Breast Cancer who have not Received any Prior Systemic Anti-Cancer Treatment for Advanced Disease

Conditions

Breast - Female

What is the purpose of this trial?

To demonstrate that the combination of PD-0332991 with letrozole is superior to placebo plus letrozole in prolonging PFS in postmenopausal women with ER(+)/HER2 (-) advance breast cancer who have not received any prior systemic anti-cancer therapies for their advanced/metastatic disease.


Participation Guidelines

Age:
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Pfizer Inc., U.S. Pharmaceuticals Group
Dates:
11/22/2013
Last Updated:
Study HIC#:
1306012292